Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2010

01-05-2010 | Poster presentation

Reduced MCPH1 expression in breast cancer and response to chemotherapy

Authors: J Richardson, A Shaaban, M Kamal, I Ellis, V Speirs, A Green, SM Bell

Published in: Breast Cancer Research | Special Issue 1/2010

Login to get access

Excerpt

Previously we identified MCPH1, a DNA damage response protein involved in the regulation of BRCA1 and BRCA2, as the defective protein in one form of microcephaly. BRCA1 mutations are associated with basal-like breast cancer, which are often also negative for oestrogen receptor (ER), progesterone receptor (PR) and HER2. Our data indicate that MCPH1 plays a role in response to chemotherapeutic agents used in the treatment of breast cancer due to its role in DNA repair and the spindle checkpoint. …
Metadata
Title
Reduced MCPH1 expression in breast cancer and response to chemotherapy
Authors
J Richardson
A Shaaban
M Kamal
I Ellis
V Speirs
A Green
SM Bell
Publication date
01-05-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2538

Other articles of this Special Issue 1/2010

Breast Cancer Research 1/2010 Go to the issue

Poster presentation

Transcriptional regulation of cyclin-dependent kinase inhibitor 1A (P21) by the transcription factor AP-2γ

Poster presentation

A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations

Poster presentation

Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins

Oral presentation

Transforming growth factor-beta co-receptor endoglin suppresses breast cancer invasion and metastasis

Oral presentation

Differentiation therapy: targeting breast cancer stem cells to reduce resistance to radiotherapy and chemotherapy

Poster presentation

Microarray based expression profiling of BRCA1 mutated human tumours using a breast-specific platform to identify a profile of BRCA1 deficiency
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits